Precigen/$PGEN
1D1W1MYTD1Y5YMAX
About Precigen
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
- Ticker
- $PGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 160
- Headquarters
- Germantown, United States
- Website
- precigen.com
Precigen Metrics
BasicAdvanced
$2.7B
-
-$0.98
1.01
-
Price and volume
Market cap
$2.7B
Beta
1.01
52-week high
$7.49
52-week low
$2.99
Average daily volume
5.2M
Financial strength
Current ratio
4.578
Quick ratio
3.756
Long term debt to equity
223.265
Total debt to equity
225.686
Interest coverage (TTM)
-4.06%
Profitability
EBITDA (TTM)
-35.359
Gross margin (TTM)
53.01%
Net profit margin (TTM)
-183.98%
Operating margin (TTM)
-46.08%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-18.14%
Return on equity (TTM)
-837.08%
Valuation
Price to revenue (TTM)
29.789
Price to book
61.13
Price to tangible book (TTM)
103.24
Price to free cash flow (TTM)
-22.161
Free cash flow yield (TTM)
-4.51%
Free cash flow per share (TTM)
-0.336
Growth
Revenue change (TTM)
1,875.05%
Earnings per share change (TTM)
129.04%
3-year revenue growth (CAGR)
57.11%
10-year revenue growth (CAGR)
-7.69%
3-year earnings per share growth (CAGR)
113.93%
10-year earnings per share growth (CAGR)
-4.69%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Precigen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.